US EditionKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
- Kodiak Sciences Inc. Reported its first quarter 2025 business highlights and financial results from Palo Alto, California on May 14, 2025.
- Kodiak is advancing its pipeline focused on next-generation retinal therapies, progressing three Phase 3 candidates with expected primary data release scheduled for 2026.
- The company detailed clinical progress of tarcocimab in diabetic retinopathy, retinal vein occlusion, and wet AMD, and ongoing studies for KSI-501 and KSI-101 targeting retinal vascular diseases.
- Kodiak recorded a net loss of $57.5 million or $1.09 per share for Q1 2025, with $43.6 million in R&D expenses driven by clinical and manufacturing activities, and $138.9 million cash at quarter end.
- Kodiak stated it expects current cash to fund operations into 2026 while cautioning that development risks, regulatory uncertainties, and economic conditions may affect results and timelines.
Insights by Ground AI
Does this summary seem wrong?
28 Articles
28 Articles
All
Left
2
Center
10
Right
Montana Standard+27 Reposted by 27 other sources
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025.
Coverage Details
Total News Sources28
Leaning Left2Leaning Right0Center10Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
